Search

Displaying results 1431 - 1440 of 10000 in total
  1. Drug

    Daratumumab

    go.drugbank.com/drugs/DB09331
    ApprovedInvestigational

    In July 2024, it was further approved in combination with bortezomib, lenalidomide, and dexamethasone (D-VRd) for induction and consolidation therapy in newly diagnosed, transplant-eligible patients. … [A7935] It was first described in the literature in 2010 as a monoclonal antibody that targets CD38+ multiple myeloma cells; the first of its kind.

  2. Drug

    Estetrol

    go.drugbank.com/drugs/DB12235
    ApprovedInvestigational

    Estetrol is the first new estrogen introduced to the USA in over 50 years and is the first approved estetrol product in the world. … [L33179] In Canada, Nextstellis was approved for use in March 2021; it was developed by Mithra and is marketed by Searchlight Pharma.[L33209]

  3. Drug

    Tezepelumab

    go.drugbank.com/drugs/DB15090
    ApprovedInvestigational

    [L39504] Tezepelumab was also approved by the European Commission on September 19, 2022.[L44712] … It was granted FDA approval on December 17, 2021, and is currently marketed under the trademark TEZSPIRE by Amgen/AstraZeneca.

  4. Drug

    Ciltacabtagene autoleucel

    go.drugbank.com/drugs/DB16738
    ApprovedInvestigational

    a range of symptoms including bone pain, hematologic abnormalities, and end-organ damage. … [A245854] While normally expressed on plasma blasts and plasma cells, BCMA is widely expressed on malignant plasma cells and most multiple myeloma cell lines, making it a choice target in the development

  5. Drug

    Rimegepant

    go.drugbank.com/drugs/DB12457
    ApprovedInvestigational

    safer for use in patients with contraindications to standard therapy. … Rimegepant is an oral antagonist of the CGRP receptor developed by Biohaven Pharmaceuticals.

  6. Drug

    Triclabendazole

    go.drugbank.com/drugs/DB12245
    ApprovedInvestigational

    Triclabendazole, manufactured by Novartis pharmaceuticals, is an antihelminthic drug that was approved by the FDA in February 2019 for the treatment of fascioliasis in humans. … Triclabendazole was previously used in the treatment of fascioliasis in livestock, but is now approved for human use.

  7. Drug

    Teduglutide

    go.drugbank.com/drugs/DB08900
    ApprovedInvestigational

    FDA approved on December 21, 2012.

    Categories: Compounds used in a research, industrial, or household setting
  8. Drug

    Scarlet red

    go.drugbank.com/drugs/DB19136
    ApprovedWithdrawn

    Scarlet red is under investigation in clinical trial NCT00591916 (New Treatment for Donor Sites).

    Categories: Compounds used in a research, industrial, or household setting
  9. Drug

    Alternaria alternata

    go.drugbank.com/drugs/DB10424
    Approved

    Alternaria alternata extract is used in allergenic testing.

    Mixtures: Number Ten Mold Mixture, Number Ten Mold Mixture
  10. Drug

    Ribavirin

    go.drugbank.com/drugs/DB00811
    ApprovedInvestigational

    Combination therapy of ribavirin and [DB00008] results in the SVR of 44% in patients with genotype 1 infection and 70% in patients with genotype 2-6. … in HCV genotype 4 patients [L852].

    Mixtures: Rebetron Solution (albumin (human) Free) (18 Miu Multi-dose Pen / 200mg Capsules)